SEBI Reg. Investment Advisor

Download App

Help Center Subscribe

Recent:

Log In Sign Up Schedule Free 15‑min Call

Top Pharma Companies in India by Market Cap

BSE Sensex 78180.72
104.35 (-0.13%)

Filter

Top Pharma Companies in India as on Jul-2026 | 5 Star Rated Stocks Undervalued Stocks Fair Valued Stocks Uptrend Stocks

Filter

	Company Name	DeciZen	Market cap (Rs. Cr.)	CMP (Change %)	Latest P/E	Latest P/BV	5Y Sales Gr.(%)	5Y Profit Gr.(%)
121	Anuh Pharma Ltd.	Q V+ PT	809 Small Cap	79.02 (-2.13%)	19.71	2.3	16.60	20.73	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
122	Morepen Laboratories Ltd.	Q V PT	3,330 Small Cap	61 (0.36%)	50.42	2.68	14.44	19.03	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
123	Fischer Medical Ventures Ltd.	Q V PT	2,479 Small Cap	38.10 (0.61%)	N/A	7.94	96.10	0.00	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
124	Sigachi Industries Ltd.	Q V+ PT	844 Small Cap	21.75 (-1.58%)	N/A	1.77	24.05	7.49	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
125	Syncom Formulations (India) Ltd.	Q V PT	1,315 Small Cap	13.92 (-0.50%)	17.3	3.19	17.63	21.67	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
126	Nectar Lifesciences Ltd.	Q V PT	225 Small Cap	11.22 (-3.03%)	N/A	0.39	-6.71	-232.05	Add to Portfolio Add to Watchlist Decision Maker P/E Chart Dividend History
Prev 1 2 3 4 5 Next

Screens:

AlphaCases Top Rated Stocks Best Nifty Stocks Best Nifty Next Stocks Best Nifty 500 Stocks Best SmallCap Stocks Top BFSI Stocks

Pharma - Today's Top Gainers

Company Name	CMP	Price Change(%)
IOL Chem & Pharma	164.95	14.23%
Natco Pharma	984.35	5.65%
Bliss GVS Pharma	511.55	4.69%
Akums Drugs & Pharma	650.60	4.21%
Gland Pharma	2,551	3.60%

Pharma - Today's Top Losers

Company Name	CMP	Price Change(%)
Fermenta Biotech	368.90	-6.61%
KMC Speciality Hosp.	128.45	-4.46%
Biocon	406.90	-4.18%
Kwality Pharma	2,548.05	-3.96%
Themis Medicare	116.65	-3.60%

News about Top Pharma Companies in India

01

Jul, 2026

Morepen Laboratories informs about press releases

Morepen Laboratories has informed that it enclosed press release with the title ‘Morepen starts commercial supplies under its ? 825 Crore CDMO mandate’.

The above information is a part of company’s filings submitted to BSE.

01

Jun, 2026

Sigachi Industries informs about newspaper publication

Sigachi Industries has informed that the Audited Financial Results (Standalone & Consolidated) of Sigachi Industries for the quarter and year ended March 31, 2026, as approved in the Board Meeting held on May 30, 2026 and public notice to Shareholders regarding 100 days campaign-Saksham Niveshak for updation of their KYC and other relevant details and claim their unpaid/unclaimed dividends, have been published on May 31, 2026 in the following newspapers: 1. Financial Express 2. Nava Telangana

The above information is a part of company’s filings submitted to BSE.

30

May, 2026

Fischer Medical Ventures informs about outcome of board meeting

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, Fischer Medical Ventures has informed that the Board of Directors of the Company, at its meeting held on 29th May considered and recommended a final dividend of 5% i.e. Rs. 0.05/- per equity share of face value Re. 1/- each for the financial year ended 31st March 2026. The said dividend, if declared and approved by the members at the ensuing Annual General Meeting (‘AGM’), shall be paid/dispatched within 30 days from the date of the AGM.

The above information is a part of company’s filings submitted to BSE.

27

May, 2026

Morepen Laboratories informs about newspaper publication

Morepen Laboratories has informed that pursuant to Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, it has enclosed newspapers dated 27th May 2026 pertaining to the financial results for the quarter and financial year ended on 31st March 2026: i. Financial Express (English), ii. Jansatta (Hindi). The copy of newspaper advertisements is attached. These are also being made available on the website of the company at www.morepen.com.

The above information is a part of company’s filings submitted to BSE.

27

May, 2026

Morepen Laboratories informs about press release

Morepen Laboratories has informed that it enclosed press release with the titled, ‘Morepen Labs Q4 Net Profit Rises 69%; CDMO Program Moves into Commercial Execution; Board Proposes a Dividend of 10% to the shareholders for FY26’.

The above information is a part of company’s filings submitted to BSE.

27

May, 2026

Morepen Laboratories informs about investor presentation

Morepen Laboratories has informed that it enclosed the Investor Presentation – Q4 & FY26 based on the financial performance of the company for the quarter and financial year ended 31st March 2026.

The above information is a part of company’s filings submitted to BSE.

Publicly traded pharmaceuticals

Top 10 Publicly Listed pharmaceutical stocks in India by Market Capitalization as of 2026.

Rank	Company	Market Capitalization 2026 (INR crores)
1	Abbott India Ltd.	57,058 Crore
2	Neuland Laboratories Ltd.	24,196 Crore
3	Apollo Hospitals Enterprise Ltd.	1,27,858 Crore
4	Astrazeneca Pharma India Ltd.	20,556 Crore
5	Divis Laboratories Ltd.	1,81,867 Crore
6	Procter & Gamble Health Ltd.	10,493 Crore
7	Kovai Medical Center & Hospital Ltd.	6,580 Crore
8	Alkem Laboratories Ltd.	66,927 Crore
9	Dr Agarwals Eye Hospital Ltd.	2,419 Crore
10	Torrent Pharmaceuticals Ltd.	1,63,246 Crore

Do you know? Asking 3 Right Questions minimizes the RISK of Stock Investing To Know

Right Stock | Right Price | Right Allocation

Find best stocks to buy now Find best pharma stocks to buy now

Top 15 Pharma Stocks by Revenue Growth

Top Pharma Companies Source: NSE Indices

You can use different criterias to arrive at the list of best stocks in the Nifty Pharma company index. You can use return ratios like ROCE or ROE, that will help you choose companies with profitable growth.

Based on ROE, the best stocks in the Nifty Pharma companies index are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	ROE
Abbott India Ltd. (M)	Very Good	26,690	57,058	36.76	11.95	25.14	35.71
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,853	1,63,246	75.46	19.46	39.62	29.04
Ajanta Pharma Ltd. (M)	Very Good	3,311	42,118	39.88	9.31	26.95	25.35
Lupin Ltd. (M)	Somewhat Good	2,490	1,13,963	21.37	5.08	12.36	20.83
Zydus Lifesciences Ltd. (M)	Very Good	1,153	1,14,518	22.72	4.40	13.90	20.74

Based on the past year's gain, the best performing stocks are:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	Yearly gain (%)
Laurus Labs Ltd. (M)	Very Good	1,477	82,615	97.06
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,423	38,385	46.04
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,853	1,63,246	43.21
Aurobindo Pharma Ltd. (M)	Very Good	1,582	91,709	33.87
Gland Pharma Ltd. (S)	Very Good	2,551	40,621	31.41
				View More

Stocks with the highest revenue growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Sales Growth (%)
JB Chemicals & Pharmaceuticals Ltd. (S)	Very Good	2,423	38,385	56.94	9.51	34.49	15.51
Mankind Pharma Ltd. (M)	Very Good	2,530	1,04,911	51.49	6.40	32.31	14.65
Ajanta Pharma Ltd. (M)	Very Good	3,311	42,118	39.88	9.31	26.95	13.54
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,354	1,14,246	27.23	3.03	15.19	12.09
Torrent Pharmaceuticals Ltd. (L)	Very Good	4,853	1,63,246	75.46	19.46	39.62	11.80

Stocks with high profit growth often witness their stock prices gaining, irrespective of the market movements.

Stocks with the highest profit growth in the past 5 years is:

Company Name	Is it a Right Stock ?	CMP	Market Cap(Cr.)	P/E	P/BV	EV/EBITDA	5Y Profit Growth (%)
Zydus Lifesciences Ltd. (M)	Very Good	1,153	1,14,518	22.72	4.40	13.90	30.57
Sun Pharmaceutical Industries Ltd. (L)	Very Good	1,903	4,59,005	39.98	5.49	22.91	23.50
Abbott India Ltd. (M)	Very Good	26,690	57,058	36.76	11.95	25.14	18.78
Dr. Reddys Laboratories Ltd. (M)	Very Good	1,354	1,14,246	27.23	3.03	15.19	15.75
Glenmark Pharmaceuticals Ltd. (M)	Very Good	2,257	64,072	47.05	6.10	12.50	14.41

You have 9 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login | Register Now

Create stable, long-term investment portfolio with strong, consistent stocks.

Start Research-backed Investing ...Now. Subscribe to Sapphire

2026 ©The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me® is a registered trademark of The Alchemists Ark Pvt. Ltd.

About MoneyWorks4Me

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Fiduciary-first advisory model.
As SEBI-registered IAs, we are legally and ethically bound to act in the best interests of our clients. We do not sell or distribute any financial products. This ensures our guidance is 100% unbiased and conflict-free.
Deep fundamental research + robust valuation discipline.
Built on more than 15 years of equity research, our framework combines quality assessment, intrinsic value estimation, and a sensible margin-of-safety approach.
Process—not predictions.
We don’t rely on guesswork or market timing. Instead, we focus on asset allocation, risk management, and long-term compounding.
Technology + Human Intelligence.
We believe a combination of both is essential for investing success. We constantly innovate and upgrade in-house tools, financial X-rays, and portfolio analytics so that our team of analysts and advisors are equipped with the best.
Partner with Clients.
We follow a DIWM (Do-It-With-Me) approach where we partner clients in setting goals, financial planning, educating on our investing process and share decision-enabling resources transparently with our clients who retain control on execution.

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

Investing in stocks, mutual funds, debt, and gold
Quality-at-Reasonable-Price way of investing in stocks
Constructing Direct Stock Portfolios with Core, Booster, and Amplifier stocks
A Mutual Fund Portfolio that delivers consistent out-performance and meaningful diversification (low overlap)
Periodic review and rebalancing
Clear Buy-Sell-Hold, and Position-sizing frameworks